Actieve protocollen
Actieve protocollen:
- Advies CML behandeld met imatinib
- Advies Craniopharyngeoom
- Afatinib
- ALD-103
- ALL SCTped 2012 FORUM
- ALL-11
- Aplastische Anemie
- Aprepitant PK pilot study
- BEACON
- BIOMEDE
- Blinatumomab in infant ALL
- Blinatumomab therapy
- Blinatumomab_
- Bosutinib
- CA209744
- CA209908
- Catecholamine protocol
- CIP
- Clofarabine based therapy
- CRISP
- Dabrafenib (DRB436)
- DaratumumabALL2005
- DexaDagen-2
- Diagnostiek Beenmergfalen
- EpSSG metastatic STS
- ESMART
- EsPhALL2017/COGAALL1631
- ETB115
- EuroNet-PHL-C2
- EuroNet-PHL-LP1
- EWOG/MDS 2006
- EZH-102
- Fanconi Anemie
- Fertility add-on EuroNet-PHL-C2
- HLH Registry
- Hodgkin Biomarker add-on EuroNet-PHL-C2
- I-CML-Ped Study
- Ibrutinib
- ICC APL Study 01 en 02
- Inotuzumab Ozogamicin- InO studie
- Inter-B-NHL Ritux 2010
- Interfant 2006
- Internationale richtlijnen voor CML
- IntReALL HR 2010
- IntReALL SR 2010
- ITHER Protocol
- LCH-IV
- LOXO-TRK-15003
- M13-833 (Venetoclax)
- M14-483
- MICADO-1
- MICADO-2
- MIFI
- Moleculaire MRD monitoring
- MRD in NBL
- MRI Ciproxin
- NB-SCI
- NB2013 HR pilot GPOH/DCOG
- Nelarabine based therapy
- Nicord III
- NOPHO-DBH AML 2012
- Pinocchio
- PROTECT
- REACH-2
- REACH-3
- Relapse Registry 2009/Recidief AML 2001/01
- SENSORY
- SIOPE DIPG Registry
- SKION B-NHL/B-ALL 2008
- SO-PEWS
- TMD bij Down Syndroom
- TuPS
- Umbrella protocol - SIOP-RTSG 2016
- VIDAZA relapse MDS/JMML
- ViNiLo
- WES-KidTs
- ZUMA-4